在健康人群中提高1升聚乙二醇联合低剂量抗坏血酸肠道准备耐受性与安全性的随机多中心临床试验
这项随机、双盲、多中心、非劣效试验纳入215名健康成人,比较1升聚乙二醇联合低剂量抗坏血酸与标准1升及2升聚乙二醇抗坏血酸的肠道准备效果。结果显示低剂量抗坏血酸组清洁效能相似,耐受性优于2升方案,胃内残留液体少于标准1升方案。
要点
- 1升聚乙二醇联合低剂量抗坏血酸的肠道清洁效能与标准1升及2升方案相似(所有P > .1)。
- 低剂量抗坏血酸组耐受性优于2升聚乙二醇抗坏血酸,胃内残留液体少于标准1升方案。
- 总体不良事件、轻度不良事件、死亡及胃十二指肠糜烂或溃疡发生率无显著差异。
核心结论
- 1升聚乙二醇联合低剂量抗坏血酸(剂量减少25%-50%)的肠道清洁效能和安全性与标准1升或2升聚乙二醇抗坏血酸相似,耐受性优于2升方案,胃内残留液体少于标准1升方案。
研究设计与样本
- 随机、对照、双盲、多中心、非劣效试验,纳入2020年6月至2021年1月接受结肠镜检查的215名健康成人。
- 比较1升聚乙二醇联合低剂量抗坏血酸(A组抗坏血酸浓度降低50%,B组和C组降低25%)与标准1升及2升聚乙二醇抗坏血酸,所有方案均为分次给药。
主要发现
- 根据Harefield清洁量表和波士顿肠道准备量表,1升聚乙二醇联合低剂量抗坏血酸(A-C组)与标准1升及2升聚乙二醇抗坏血酸清洁效能相似,无负面临床表现(所有P > .1)。
- 1升聚乙二醇联合低剂量抗坏血酸相比2升聚乙二醇抗坏血酸耐受性更好,相比1升聚乙二醇抗坏血酸胃内残留液体更少,与抗坏血酸剂量成比例。
- 总体不良事件、轻度不良事件、死亡以及上消化道内镜检查发现的胃十二指肠糜烂或溃疡发生率均无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: One-liter polyethylene glycol plus ascorbic acid (PEG-ASC) improves patient tolerability, but some patients still show low tolerability to a relatively high content of ASC. This study aimed to improve the tolerability and safety of 1-L PEG with low-dose ASC in comparison with standard 1-L and 2-L PEG-ASC. METHODS: This was a randomized, controlled, double-blinded, multicenter, noninferiority trial involving 215 healthy adults who underwent colonoscopy from June 2020 to January 2021. Efficacy, tolerability, and safety were compared among 1-L PEG with low-dose ASC (50% lower ASC concentration in group A and 25% lower ASC concentration in groups B and C) and standard 1-L and 2-L PEG-ASC with all split regimens. RESULTS: One-liter PEG with low-dose ASC (groups A-C) had similar bowel cleansing efficacies according to the Harefield Cleansing Scale and Boston Bowel Preparation Scale, without negative clinical performance, compared with standard 1-L and 2-L PEG-ASC preparation (all P > .1). One-liter PEG with low-dose ASC had better tolerability compared with 2-L PEG-ASC and less residual fluid retention in the stomach compared with 1-L PEG-ASC, proportional to the amount of ASC. No significant differences were found in the incidences of overall adverse events, mild adverse events, or death or in the occurrence of gastroduodenal erosion or ulcer in upper endoscopy. CONCLUSIONS: One-liter PEG with low-dose ASC (25%-50% reduction in dose) for bowel cleansing showed similar efficacy and safety compared with standard 1-L or 2-L PEG-ASC, better tolerability compared with 2-L PEG-ASC, and less residual gastric fluid retention compared with standard 1-L PEG-ASC. (Clinical trial registration number: KCT0005490.).
引用
- Jung Y, Kang SB, Yoon HJ, et al. Improving the tolerability and safety of 1-L polyethylene glycol plus low-dose ascorbic acid for bowel preparation in a healthy population: a randomized multicenter clinical trial. Gastrointest Endosc. 2022. PMID: 35288148. doi:10.1016/j.gie.2022.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。